Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone Versus Bortezomib with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Inclusion Criteria

• Able to provide informed consent.
• Male or female, 18 years or older.
• Diagnosed with multiple myeloma according to specific medical criteria.
• In good general health with a performance status score of 0 to 2.
• Previously treated with at least one line of therapy for multiple myeloma, including a regimen with lenalidomide, and have shown disease progression during or after the last treatment.
• Have at least one measurable sign of the disease, such as specific levels of proteins in the blood or urine.
• Have had a stem cell transplant or are not eligible for one. If previously transplanted, it must have been over 100 days ago and without active infections.
• Any previous treatment side effects must be mild or resolved, except for hair loss.
• Have adequate organ function as specified in the study protocol.
• Agree to use effective birth control methods as required by the study.

Exclusion Criteria

• Have active plasma cell leukemia, amyloidosis, or certain other conditions at screening.
• Have had an allogeneic stem cell transplant.
• Have received anti-myeloma treatment or certain medications recently before starting the study.
• Have had plasmapheresis within 7 days before starting the study.
• Have been treated with or cannot tolerate pomalidomide.
• Have received treatment targeting BCMA.
• Cannot tolerate or did not respond to bortezomib.
• Have certain heart conditions or recent heart events.
• Have had major surgery in the last 4 weeks.
• Have another invasive cancer, unless stable for at least 2 years or only receiving hormonal therapy.
• Have allergies to study drugs or their components.
• Have active bleeding or certain liver diseases.
• Have active infections requiring treatment.
• Have HIV, hepatitis B, or hepatitis C unless meeting specific criteria.
• Have severe kidney conditions or other conditions affecting safety.
• Have significant nerve pain or damage.
• Have had blood clots in the last 3 months.
• Cannot or will not take required blood clot prevention.
• Have certain eye diseases.
• Have serious or unstable medical or psychiatric conditions.
• Are pregnant or breastfeeding.